Source link : https://www.newshealth.biz/health-news/fda-oks-new-option-for-primary-biliary-cholangitis/
The FDA granted accelerated approval to seladelpar (Livdelzi) for adults with primary biliary cholangitis (PBC), a rare and chronic autoimmune disease of the bile ducts, drugmaker Gilead Sciences announced on Wednesday. An oral peroxisome proliferator-activated receptor (PPAR)-delta agonist, seladelpar is indicated for use in combination with ursodeoxycholic acid (UDCA) for patients with an inadequate response […]
Author : News Health
Publish date : 2024-08-14 20:47:51
Copyright for syndicated content belongs to the linked Source.
Categories